spacer
home > ebr > autumn 2018 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Fewer than 10 advanced therapy medicinal products (ATMPs) are currently licensed for use in Europe. The R&D pipeline of early stage ATMP candidates is strong at present, but the manifold challenges (including chemistry, manufacturing and controls, clinical trials, and complex regulatory pathways) to bringing these potentially transformational therapies to market are such that it will take considerable time before their full potential in healthcare is realised. In this autumn 2018 edition of EBR, The Christie Hospitalís Dr Fiona Thistlethwaite and Aptus Clinicalís Dr Ian Thomas introduce the Innovate UK-funded iMatch consortium of clinical and commercial researchers, who will aim to overcome some of the key barriers to successful progression of ATMPs and their scale-up for a range of chronic debilitating conditions (page 14). A major therapeutic focus of ATMP development is oncology, spearheaded by the recently approved Kymriah, for acute B-cell lymphoblastic lymphoma, and Yescarta, for non-Hodgkin lymphoma, from Novartis and Kite/ Gilead respectively. These classes of drug are one of the precision therapies included in N-of-Oneís Dr Kathryn D Bungartzís comprehensive summary of the current cancer therapy innovation landscape (page 56). So too are antibody-drug conjugates, the challenges in production of which and the potential means to circumvent are discussed by the Sanofi and Merck Group teams (page 80).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

CBIs Global Risk Based Monitoring Event

CBIís Global Risk Based Monitoring Event is approaching, taking place in London on 13 Ė 14 September 2018, designed for benchmarking with international peers to gauge RBM performance, efficiencies, implementation and technologies.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

SCOPE Europe: Summit for Clinical Ops Executives

16-17 October 2018, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops execs, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the Rest of the World.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement